Repurposing Rapamycin: A Report On the First Biomarker-Driven Treatment Trial for ME/CFS

In 2025, Simmaron Research was the second recipient of Solve’s ME/CFS Catalyst Award in support of its study, “Low Dose Rapamycin in ME/CFS, Long-COVID, and Other Infection-Associated Chronic Conditions.” The study hypothesizes that mTOR inhibition through rapamycin may address observed findings of autophagy impairment and symptoms in a subset of patients with ME/CFS and other infection-associated chronic conditions and illnesses (IACCIs).  

The study advances an already FDA-approved drug for reducing key symptoms of ME/CFS and Long Covid, repurposing rapamycin to reduce fatigue, orthostatic intolerance, post-exertional malaise, and sleep issues for a subset of people with ME/CFS.

In this webinar hosted by Solve M.E. President Emily Taylor, panelists Courtney Miller (Board President at Simmaron), Dr. C. Gunnar Gottschalk (Chief Executive Officer at Simmaron), and Dr. Avik Roy (Chief Scientific Officer at Simmaron) will discuss the latest learnings from the study, and their plan to conduct an  NIH exploratory treatment trial based on the data.